A longitudinal study evaluating the effects of interferon-alpha therapy on cognitive and psychiatric function in adults with chronic hepatitis C

Marilyn Huckans, Bret Fuller, Viva Wheaton, Sarah Jaehnert, Carilyn Ellis, Michael Kolessar, Daniel Kriz, Jeanne Renee Anderson, Kristin Berggren, Hannah Olavarria, Anna W. Sasaki, Michael Chang, Kenneth D. Flora, Jennifer M. Loftis

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Objective: To prospectively evaluate for changes in objective cognitive performance (attention, memory, and executive function) and psychiatric symptom severity (depression, anxiety, fatigue, and pain) in patients before, during and after interferon-alpha based therapy (IFN) for chronic hepatitis C virus infection (HCV). Methods: 33 HCV. + adults were evaluated two months before IFN initiation (baseline), three months into IFN, and six months following IFN termination (IFN. + Group). 31 HCV. + adults who did not undergo IFN therapy were evaluated at baseline and six months later (IFN. - Group). At each evaluation, participants completed the Neuropsychological Assessment Battery (NAB) Attention, Memory and Executive Functions Modules, the Beck Depression Inventory, Second Edition (BDI), Generalized Anxiety Disorder Inventory (GADI), Fatigue Severity Scale (FSS), and Brief Pain Inventory (BPI). Results: Compared with the IFN. - Group, the IFN. + Group experienced significantly (p. <. 0.050) increased symptoms of depression, anxiety, fatigue and pain during IFN therapy relative to baseline. In the IFN. + Group, psychiatric symptoms generally returned to baseline levels following IFN termination. Sustained viral response was associated with significantly lower depression and fatigue. No significant changes in cognitive performance were observed. Conclusions: During IFN, patients with HCV evidence significantly increased psychiatric symptoms, including symptoms of depression, anxiety, fatigue and pain. These psychiatric symptoms are generally short-term and remit following IFN termination, with increased benefit if viral clearance is achieved. However, IFN is not associated with significant declines in objective cognitive performance during or following IFN.

Original languageEnglish (US)
Pages (from-to)184-192
Number of pages9
JournalJournal of Psychosomatic Research
Volume78
Issue number2
DOIs
StatePublished - Jan 1 2015

Fingerprint

Chronic Hepatitis C
Interferon-alpha
Cognition
Fatigue
Psychiatry
Longitudinal Studies
Virus Diseases
Hepacivirus
Depression
Pain
Anxiety
Executive Function
Equipment and Supplies
Therapeutics
Anxiety Disorders

Keywords

  • Anxiety
  • Cognition
  • Depression
  • Fatigue
  • Hepatitis c
  • Interferon
  • Pain

ASJC Scopus subject areas

  • Clinical Psychology
  • Psychiatry and Mental health

Cite this

A longitudinal study evaluating the effects of interferon-alpha therapy on cognitive and psychiatric function in adults with chronic hepatitis C. / Huckans, Marilyn; Fuller, Bret; Wheaton, Viva; Jaehnert, Sarah; Ellis, Carilyn; Kolessar, Michael; Kriz, Daniel; Anderson, Jeanne Renee; Berggren, Kristin; Olavarria, Hannah; Sasaki, Anna W.; Chang, Michael; Flora, Kenneth D.; Loftis, Jennifer M.

In: Journal of Psychosomatic Research, Vol. 78, No. 2, 01.01.2015, p. 184-192.

Research output: Contribution to journalArticle

Huckans, M, Fuller, B, Wheaton, V, Jaehnert, S, Ellis, C, Kolessar, M, Kriz, D, Anderson, JR, Berggren, K, Olavarria, H, Sasaki, AW, Chang, M, Flora, KD & Loftis, JM 2015, 'A longitudinal study evaluating the effects of interferon-alpha therapy on cognitive and psychiatric function in adults with chronic hepatitis C', Journal of Psychosomatic Research, vol. 78, no. 2, pp. 184-192. https://doi.org/10.1016/j.jpsychores.2014.07.020
Huckans, Marilyn ; Fuller, Bret ; Wheaton, Viva ; Jaehnert, Sarah ; Ellis, Carilyn ; Kolessar, Michael ; Kriz, Daniel ; Anderson, Jeanne Renee ; Berggren, Kristin ; Olavarria, Hannah ; Sasaki, Anna W. ; Chang, Michael ; Flora, Kenneth D. ; Loftis, Jennifer M. / A longitudinal study evaluating the effects of interferon-alpha therapy on cognitive and psychiatric function in adults with chronic hepatitis C. In: Journal of Psychosomatic Research. 2015 ; Vol. 78, No. 2. pp. 184-192.
@article{ab2691e9825f4fddb9c01468e00aee20,
title = "A longitudinal study evaluating the effects of interferon-alpha therapy on cognitive and psychiatric function in adults with chronic hepatitis C",
abstract = "Objective: To prospectively evaluate for changes in objective cognitive performance (attention, memory, and executive function) and psychiatric symptom severity (depression, anxiety, fatigue, and pain) in patients before, during and after interferon-alpha based therapy (IFN) for chronic hepatitis C virus infection (HCV). Methods: 33 HCV. + adults were evaluated two months before IFN initiation (baseline), three months into IFN, and six months following IFN termination (IFN. + Group). 31 HCV. + adults who did not undergo IFN therapy were evaluated at baseline and six months later (IFN. - Group). At each evaluation, participants completed the Neuropsychological Assessment Battery (NAB) Attention, Memory and Executive Functions Modules, the Beck Depression Inventory, Second Edition (BDI), Generalized Anxiety Disorder Inventory (GADI), Fatigue Severity Scale (FSS), and Brief Pain Inventory (BPI). Results: Compared with the IFN. - Group, the IFN. + Group experienced significantly (p. <. 0.050) increased symptoms of depression, anxiety, fatigue and pain during IFN therapy relative to baseline. In the IFN. + Group, psychiatric symptoms generally returned to baseline levels following IFN termination. Sustained viral response was associated with significantly lower depression and fatigue. No significant changes in cognitive performance were observed. Conclusions: During IFN, patients with HCV evidence significantly increased psychiatric symptoms, including symptoms of depression, anxiety, fatigue and pain. These psychiatric symptoms are generally short-term and remit following IFN termination, with increased benefit if viral clearance is achieved. However, IFN is not associated with significant declines in objective cognitive performance during or following IFN.",
keywords = "Anxiety, Cognition, Depression, Fatigue, Hepatitis c, Interferon, Pain",
author = "Marilyn Huckans and Bret Fuller and Viva Wheaton and Sarah Jaehnert and Carilyn Ellis and Michael Kolessar and Daniel Kriz and Anderson, {Jeanne Renee} and Kristin Berggren and Hannah Olavarria and Sasaki, {Anna W.} and Michael Chang and Flora, {Kenneth D.} and Loftis, {Jennifer M.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.jpsychores.2014.07.020",
language = "English (US)",
volume = "78",
pages = "184--192",
journal = "Journal of Psychosomatic Research",
issn = "0022-3999",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - A longitudinal study evaluating the effects of interferon-alpha therapy on cognitive and psychiatric function in adults with chronic hepatitis C

AU - Huckans, Marilyn

AU - Fuller, Bret

AU - Wheaton, Viva

AU - Jaehnert, Sarah

AU - Ellis, Carilyn

AU - Kolessar, Michael

AU - Kriz, Daniel

AU - Anderson, Jeanne Renee

AU - Berggren, Kristin

AU - Olavarria, Hannah

AU - Sasaki, Anna W.

AU - Chang, Michael

AU - Flora, Kenneth D.

AU - Loftis, Jennifer M.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Objective: To prospectively evaluate for changes in objective cognitive performance (attention, memory, and executive function) and psychiatric symptom severity (depression, anxiety, fatigue, and pain) in patients before, during and after interferon-alpha based therapy (IFN) for chronic hepatitis C virus infection (HCV). Methods: 33 HCV. + adults were evaluated two months before IFN initiation (baseline), three months into IFN, and six months following IFN termination (IFN. + Group). 31 HCV. + adults who did not undergo IFN therapy were evaluated at baseline and six months later (IFN. - Group). At each evaluation, participants completed the Neuropsychological Assessment Battery (NAB) Attention, Memory and Executive Functions Modules, the Beck Depression Inventory, Second Edition (BDI), Generalized Anxiety Disorder Inventory (GADI), Fatigue Severity Scale (FSS), and Brief Pain Inventory (BPI). Results: Compared with the IFN. - Group, the IFN. + Group experienced significantly (p. <. 0.050) increased symptoms of depression, anxiety, fatigue and pain during IFN therapy relative to baseline. In the IFN. + Group, psychiatric symptoms generally returned to baseline levels following IFN termination. Sustained viral response was associated with significantly lower depression and fatigue. No significant changes in cognitive performance were observed. Conclusions: During IFN, patients with HCV evidence significantly increased psychiatric symptoms, including symptoms of depression, anxiety, fatigue and pain. These psychiatric symptoms are generally short-term and remit following IFN termination, with increased benefit if viral clearance is achieved. However, IFN is not associated with significant declines in objective cognitive performance during or following IFN.

AB - Objective: To prospectively evaluate for changes in objective cognitive performance (attention, memory, and executive function) and psychiatric symptom severity (depression, anxiety, fatigue, and pain) in patients before, during and after interferon-alpha based therapy (IFN) for chronic hepatitis C virus infection (HCV). Methods: 33 HCV. + adults were evaluated two months before IFN initiation (baseline), three months into IFN, and six months following IFN termination (IFN. + Group). 31 HCV. + adults who did not undergo IFN therapy were evaluated at baseline and six months later (IFN. - Group). At each evaluation, participants completed the Neuropsychological Assessment Battery (NAB) Attention, Memory and Executive Functions Modules, the Beck Depression Inventory, Second Edition (BDI), Generalized Anxiety Disorder Inventory (GADI), Fatigue Severity Scale (FSS), and Brief Pain Inventory (BPI). Results: Compared with the IFN. - Group, the IFN. + Group experienced significantly (p. <. 0.050) increased symptoms of depression, anxiety, fatigue and pain during IFN therapy relative to baseline. In the IFN. + Group, psychiatric symptoms generally returned to baseline levels following IFN termination. Sustained viral response was associated with significantly lower depression and fatigue. No significant changes in cognitive performance were observed. Conclusions: During IFN, patients with HCV evidence significantly increased psychiatric symptoms, including symptoms of depression, anxiety, fatigue and pain. These psychiatric symptoms are generally short-term and remit following IFN termination, with increased benefit if viral clearance is achieved. However, IFN is not associated with significant declines in objective cognitive performance during or following IFN.

KW - Anxiety

KW - Cognition

KW - Depression

KW - Fatigue

KW - Hepatitis c

KW - Interferon

KW - Pain

UR - http://www.scopus.com/inward/record.url?scp=84920878851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920878851&partnerID=8YFLogxK

U2 - 10.1016/j.jpsychores.2014.07.020

DO - 10.1016/j.jpsychores.2014.07.020

M3 - Article

C2 - 25219976

AN - SCOPUS:84920878851

VL - 78

SP - 184

EP - 192

JO - Journal of Psychosomatic Research

JF - Journal of Psychosomatic Research

SN - 0022-3999

IS - 2

ER -